MMP-12, Secreted by Pro-Inflammatory Macrophages, Targets Endoglin in Human Macrophages and Endothelial Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
25 Jun 2019
Historique:
received: 30 04 2019
revised: 07 06 2019
accepted: 18 06 2019
entrez: 28 6 2019
pubmed: 28 6 2019
medline: 18 12 2019
Statut: epublish

Résumé

Upon inflammation, monocyte-derived macrophages (MΦ) infiltrate blood vessels to regulate several processes involved in vascular pathophysiology. However, little is known about the mediators involved. Macrophage polarization is crucial for a fast and efficient initial response (GM-MΦ) and a good resolution (M-MΦ) of the inflammatory process. The functional activity of polarized MΦ is exerted mainly through their secretome, which can target other cell types, including endothelial cells. Endoglin (CD105) is a cell surface receptor expressed by endothelial cells and MΦ that is markedly upregulated in inflammation and critically involved in angiogenesis. In addition, a soluble form of endoglin with anti-angiogenic activity has been described in inflammation-associated pathologies. The aim of this work was to identify components of the MΦ secretome involved in the shedding of soluble endoglin. We find that the GM-MΦ secretome contains metalloprotease 12 (MMP-12), a GM-MΦ specific marker that may account for the anti-angiogenic activity of the GM-MΦ secretome. Cell surface endoglin is present in both GM-MΦ and M-MΦ, but soluble endoglin is only detected in GM-MΦ culture supernatants. Moreover, MMP-12 is responsible for the shedding of soluble endoglin in vitro and in vivo by targeting membrane-bound endoglin in both MΦ and endothelial cells. These data demonstrate a direct correlation between GM-MΦ polarization, MMP-12, and soluble endoglin expression and function. By targeting endothelial cells, MMP-12 may represent a novel mediator involved in vascular homeostasis.

Identifiants

pubmed: 31242676
pii: ijms20123107
doi: 10.3390/ijms20123107
pmc: PMC6627183
pii:
doi:

Substances chimiques

Endoglin 0
Inflammation Mediators 0
Macrophage Colony-Stimulating Factor 81627-83-0
Granulocyte-Macrophage Colony-Stimulating Factor 83869-56-1
Matrix Metalloproteinase 12 EC 3.4.24.65

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Ministerio de Ciencia e Innovación
ID : SAF2013-43421-R to CB; SAF2017-83785-R and SAF2014-23801 to ALC
Organisme : Consejo Superior de Investigaciones Científicas
ID : 201920E022 to CB
Organisme : Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER)
ID : ISCIII-CB06/07/0038 to CB
Organisme : Czech Republic Specific University Research
ID : SVV-260414 to PN

Références

Biochem Biophys Res Commun. 2001 Jul 13;285(2):300-7
pubmed: 11444842
J Biol Chem. 2002 Aug 9;277(32):29197-209
pubmed: 12015308
Inflamm Res. 2002 Sep;51(9):464-70
pubmed: 12365720
Anticancer Res. 2003 Mar-Apr;23(2B):1189-96
pubmed: 12820370
J Biol Chem. 1992 Sep 25;267(27):19027-30
pubmed: 1326540
Clin Exp Immunol. 1992 Oct;90(1):154-9
pubmed: 1395096
Eur J Immunol. 1992 Feb;22(2):393-7
pubmed: 1537377
Arthritis Rheum. 2004 Oct;50(10):3112-7
pubmed: 15476203
Arthritis Rheum. 2004 Oct;50(10):3275-85
pubmed: 15476218
Nat Med. 2006 Jun;12(6):642-9
pubmed: 16751767
Circulation. 2006 Nov 21;114(21):2288-97
pubmed: 17088457
Clin Infect Dis. 2007 Mar 15;44(6):841-5
pubmed: 17304458
Cardiovasc Res. 2008 May 1;78(2):203-12
pubmed: 18079100
Nature. 2008 Jul 24;454(7203):428-35
pubmed: 18650913
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
J Med Chem. 2009 Apr 9;52(7):1799-802
pubmed: 19278250
Biochim Biophys Acta. 2009 Oct;1792(10):954-73
pubmed: 19607914
Arch Med Res. 2009 Oct;40(7):590-4
pubmed: 20082874
Cancer Res. 2010 May 15;70(10):4141-50
pubmed: 20424116
Arthritis Rheum. 2010 Aug;62(8):2488-98
pubmed: 20506099
Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H959-74
pubmed: 20656886
Blood Rev. 2010 Nov;24(6):203-19
pubmed: 20870325
BMC Med. 2010 Dec 20;8:86
pubmed: 21171985
Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):528-35
pubmed: 21212406
Blood. 2011 May 12;117(19):5092-101
pubmed: 21389328
Cytokine. 2011 Nov;56(2):192-9
pubmed: 21737300
Acta Medica (Hradec Kralove). 2011;54(2):59-62
pubmed: 21842718
Front Physiol. 2012 May 07;3:128
pubmed: 22586409
J Immunol. 2012 Aug 15;189(4):1946-54
pubmed: 22778395
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Blood. 2013 Jan 10;121(2):403-15
pubmed: 23074273
Circulation. 2012 Nov 27;126(22):2612-24
pubmed: 23110859
J Am Heart Assoc. 2012 Dec;1(6):e001040
pubmed: 23316311
J Immunol. 2013 Mar 1;190(5):2301-10
pubmed: 23355731
J Cell Sci. 2013 Sep 1;126(Pt 17):3948-60
pubmed: 23813962
Oncogene. 2014 Jul 24;33(30):3970-9
pubmed: 24077288
J Am Coll Cardiol. 2014 Jan 7-14;63(1):1-11
pubmed: 24140662
Placenta. 2014 Feb;35 Suppl:S93-9
pubmed: 24252708
Biochim Biophys Acta. 2014 Aug;1840(8):2571-80
pubmed: 24631662
Oncotarget. 2014 Jun 15;5(11):3711-27
pubmed: 25003596
Mediators Inflamm. 2014;2014:767185
pubmed: 25114380
J Pathol. 2015 Feb;235(3):515-26
pubmed: 25319955
Front Genet. 2015 Jan 07;5:457
pubmed: 25709613
Autoimmunity. 2015 May;48(3):139-51
pubmed: 25811915
Cancer Cell. 2015 Apr 13;27(4):462-72
pubmed: 25858805
Cardiovasc Res. 2015 Aug 1;107(3):321-30
pubmed: 25990461
Nat Rev Immunol. 2015 Nov;15(11):692-704
pubmed: 26471775
Front Biosci (Landmark Ed). 2016 Jan 01;21:89-118
pubmed: 26709763
Angiogenesis. 2016 Apr;19(2):155-71
pubmed: 26850053
PLoS Genet. 2016 Mar 24;12(3):e1005935
pubmed: 27010826
Curr Atheroscler Rep. 2016 Jun;18(6):34
pubmed: 27125207
J Vasc Res. 2016;53(3-4):149-162
pubmed: 27721318
Life Sci. 2017 Apr 15;175:52-60
pubmed: 28336397
Nat Rev Cardiol. 2017 Aug;14(8):457-471
pubmed: 28406184
Exp Eye Res. 2017 Jul;160:11-20
pubmed: 28442300
J Intern Med. 2017 Nov;282(5):429-444
pubmed: 28734077
Expert Opin Ther Targets. 2017 Oct;21(10):933-947
pubmed: 28796572
Sci Rep. 2017 Sep 22;7(1):12172
pubmed: 28939895
J Immunol. 2017 Dec 15;199(12):4023-4035
pubmed: 29101312
Circ Res. 2018 Jan 5;122(1):113-127
pubmed: 29301844
J Am Heart Assoc. 2018 Feb 1;7(3):
pubmed: 29419389
J Clin Invest. 2018 Mar 1;128(3):1106-1124
pubmed: 29457790
Atherosclerosis. 2018 Apr;271:15-25
pubmed: 29459262
Dis Model Mech. 2018 Sep 21;11(9):
pubmed: 30108051
Front Cardiovasc Med. 2018 Aug 03;5:97
pubmed: 30123798
J Am Coll Cardiol. 2018 Oct 30;72(18):2181-2197
pubmed: 30360827
Front Immunol. 2018 Nov 15;9:2650
pubmed: 30524429
JCI Insight. 2019 Jan 10;4(1):null
pubmed: 30626744
Gene. 2019 May 15;696:33-39
pubmed: 30763665
J Biol Chem. 1993 Nov 15;268(32):23824-9
pubmed: 8226919
J Dermatol Sci. 1995 Sep;10(2):103-9
pubmed: 8534608
Acta Derm Venereol. 1998 Jan;78(1):19-21
pubmed: 9498020

Auteurs

Mikel Aristorena (M)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. m.aristorena@ucl.ac.uk.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. m.aristorena@ucl.ac.uk.

Eunate Gallardo-Vara (E)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. eunate.gallardo@yale.edu.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. eunate.gallardo@yale.edu.

Matej Vicen (M)

Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. matej.vicen@gmail.com.

Mateo de Las Casas-Engel (M)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. mcasas@cib.csic.es.

Luisa Ojeda-Fernandez (L)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. mluisa.ojeda@gmail.com.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. mluisa.ojeda@gmail.com.

Concepción Nieto (C)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. cnieto@cib.csic.es.

Francisco J Blanco (FJ)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. fjblanco@ugr.es.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. fjblanco@ugr.es.

Ana C Valbuena-Diez (AC)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. ac22vd@hotmail.com.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. ac22vd@hotmail.com.

Luisa M Botella (LM)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. cibluisa@cib.csic.es.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. cibluisa@cib.csic.es.

Petr Nachtigal (P)

Department of Biological and Medical Sciences, Faculty of Pharmacy in Hradec Kralove, Charles University, 500 05 Hradec Kralove, Czech Republic. nachtigal@faf.cuni.cz.

Angel L Corbi (AL)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. acorbi@cib.csic.es.

María Colmenares (M)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. maria.colmenares@cib.csic.es.

Carmelo Bernabeu (C)

Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain. bernabeu.c@cib.csic.es.
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), 28040 Madrid, Spain. bernabeu.c@cib.csic.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH